Update of the ACCORD eye study

New England Journal of Medicine

Volumn 364, Issue 2, 2011, Pages 188-189

  Chew, Emily Y ^a   Ambrosius, Walter T ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; PLACEBO; SIMVASTATIN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC RETINOPATHY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; LETTER; PRIORITY JOURNAL; SCORING SYSTEM; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 78651373856     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1011499     Document Type: Letter

References (2)

1. The ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
2. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30.